Briacell Therapeutics Has Dosed The First Patient In Its Phase 1/2 Study To Evaluate The Safety And Efficacy Of Bria-OTS, Briacell's Personalized Next Generation Immunotherapy
Briacell Therapeutics Has Dosed The First Patient In Its Phase 1/2 Study To Evaluate The Safety And Efficacy Of Bria-OTS, Briacell's Personalized Next Generation Immunotherapy
Briacell Therapeutics已经为其1/2期研究中的首位患者注射了Bria-OTS，以评估其安全性和有效性，这是Briacell的个性化下一代免疫疗法。
The study will investigate Bria-OTS alone and in combination with immune check point inhibitor tislelizumab (manufactured and supplied by BeiGene) for the treatment of metastatic breast cancer.
该研究将单独研究用于治疗转移性乳腺癌的Bria-OTS以及与免疫检查点抑制剂替雷利珠单抗（由百济神州制造和供应）联合使用。
Bria-OTS is an enhanced form of Bria-IMT, currently in pivotal Phase 3 study for metastatic breast cancer.
Bria-OTS是Bria-IMT的一种增强形式，目前正处于转移性乳腺癌的关键3期研究中。
资讯热榜
更新时间